Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeting Colorectal Cancer Initiation Cells with Type III Interferon

FY 2015-16

Summary
Colorectal cancer (CRC) is the malignant growth of cells in the colon and the rectum. There is accumulating evidence suggesting that CRC is organized in a hierarchical manner, at the apex of which are the Cancer-Initiating Cells (CIC). Furthermore, results from xenograft models and human clinical trials indicate a selective enrichment of CICs in tumours that are resistant to therapy, suggesting that targeting CICs may represent a new paradigm in CRC treatment. Recently, our lab has shown that treatment with low dose of the DNA methylation inhibitor, 5-Aza-2'-deoxycytidine (5-AZA-CdR), can target colorectal CICs through the activation of the virus sensing pathway. Upon activation of this pathway, a group of genes known as interferon stimulated genes (ISGs) are expressed and induce an anti-viral response in the cancer cells. Although it is now known that 5-AZA-CdR induces a state of viral mimicry in these cancer cells, the downstream mediators and their role in this process are not well understood. One interesting finding of 5-AZA-CdR is its selectively induction of Type III Interferon expression. This newly discovered group of interferons has drawn attention in the research community due to its preferential expression in epithelial cells. Unlike Type I interferon which induces a strong and potentially dangerous inflammatory response upon activation, Type III interferons are able to selectively target virally infected epithelial cells, at the same time sparing the host from the negative consequences of inflammation. My project will focus on further understanding the role of Type III interferons in mediating the antiviral response in CRC cells and their potential role in targeting the CIC population.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350065
Name
Ettayebi Ilias
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Colorectal Cancer Initiation Cells with Type III Interferon
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Cell Signalling; Clinical Relevance; Colorectal Cancer; Combination Therapy; Epigenetics; Immunotherapy; Targeted Therapy; Viral Mimcry
Abstract
Colorectal cancer (CRC) is the malignant growth of cells in the colon and the rectum. There is accumulating evidence suggesting that CRC is organized in a hierarchical manner, at the apex of which are the Cancer-Initiating Cells (CIC). Furthermore, results from xenograft models and human clinical trials indicate a selective enrichment of CICs in tumours that are resistant to therapy, suggesting that targeting CICs may represent a new paradigm in CRC treatment. Recently, our lab has shown that treatment with low dose of the DNA methylation inhibitor, 5-Aza-2'-deoxycytidine (5-AZA-CdR), can target colorectal CICs through the activation of the virus sensing pathway. Upon activation of this pathway, a group of genes known as interferon stimulated genes (ISGs) are expressed and induce an anti-viral response in the cancer cells. Although it is now known that 5-AZA-CdR induces a state of viral mimicry in these cancer cells, the downstream mediators and their role in this process are not well understood. One interesting finding of 5-AZA-CdR is its selectively induction of Type III Interferon expression. This newly discovered group of interferons has drawn attention in the research community due to its preferential expression in epithelial cells. Unlike Type I interferon which induces a strong and potentially dangerous inflammatory response upon activation, Type III interferons are able to selectively target virally infected epithelial cells, at the same time sparing the host from the negative consequences of inflammation. My project will focus on further understanding the role of Type III interferons in mediating the antiviral response in CRC cells and their potential role in targeting the CIC population.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ettayebi, Ilias
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~